hotspot -WSS

hotspot

author：comprehensive 2025-10-01 21:09:45 - browse：219

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Study: Black kids more likely to die after surgery than white kids

explore

knowledge

WSS

A double vaccine crisis is endangering millions of children

Providers still hesitate to prescribe buprenorphine, study finds

People with mental disorders often marry others with same

New rules on organ donation and transplantation 'will bring chaos'

Study: Black kids more likely to die after surgery than white kids

Bird flu reported in person exposed to presumably infected cattle

entertainment

hotspot

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

U.K. decision on ALS drug has neurologists, advocates up in arms

At least 13 dead in Texas as scorching temps continue

Providers still hesitate to prescribe buprenorphine, study finds

Walensky prepares to leave CDC — and Congress — behind

Scientists uncover potential path to treating deadly childhood tumor

Bright Health sells Medicare Advantage business to Molina

Covid silver lining: Unprecedented look at human immune system

Psychedelics group wrestles with new pharma identity

Drug companies' payments and gifts affect physicians' prescribing

knowledge

White House launches permanent pandemic office

FDA official pushes for dedicated emerging pathogens team

Mass General Brigham physicians react to latest merger step

Young boy dies in trial for Pfizer Duchenne gene therapy

Marvel Studios reveals new trailer for 'The Marvels': Watch here

Trial using CRISPR to edit HIV out of cells disappoints

hotspot

explore

knowledge

knowledge